Machine learning-based prediction model for responses of bDMARDs in patients with rheumatoid arthritis and ankylosing spondylitis

[1]  P. Emery,et al.  Interferon-related gene expression in response to TNF inhibitor treatment in ankylosing spondylitis patients: a pilot study. , 2021, Rheumatology.

[2]  E. Koh,et al.  Machine learning to predict early TNF inhibitor users in patients with ankylosing spondylitis , 2020, Scientific Reports.

[3]  W. Tao,et al.  Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid Arthritis , 2020, Arthritis & rheumatology.

[4]  Geun-Tae Kim,et al.  The Impact of the Amendment of the Korean National Health Insurance Reimbursement Criteria for Anti-tumor Necrosis Factor-α Agents on Treatment Pattern, Clinical Response and Persistence in Patients With Rheumatoid Arthritis , 2020, Journal of Rheumatic Diseases.

[5]  Stephen C. J. Parker,et al.  Machine Learning to Predict Anti–Tumor Necrosis Factor Drug Responses of Rheumatoid Arthritis Patients by Integrating Clinical and Genetic Markers , 2019, Arthritis & rheumatology.

[6]  K. Hellgren,et al.  Familial aggregation and heritability of ankylosing spondylitis – a Swedish nested case–control study , 2019, Rheumatology.

[7]  Dennis L. Shung,et al.  Validation of a Machine Learning Model That Outperforms Clinical Risk Scoring Systems for Upper Gastrointestinal Bleeding. , 2019, Gastroenterology.

[8]  M. Garshasbi,et al.  Genetic implications in the pathogenesis of rheumatoid arthritis; an updated review. , 2019, Gene.

[9]  C. Pontes,et al.  Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study , 2019, Arthritis Research & Therapy.

[10]  Q. Huys,et al.  Machine learning and big data in psychiatry: toward clinical applications , 2019, Current Opinion in Neurobiology.

[11]  Sebastian Raschka,et al.  Model Evaluation, Model Selection, and Algorithm Selection in Machine Learning , 2018, ArXiv.

[12]  Ioannis A. Kakadiaris,et al.  Machine Learning Outperforms ACC/AHA CVD Risk Calculator in MESA , 2018, Journal of the American Heart Association.

[13]  J. Kremer,et al.  Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial , 2018, The Lancet.

[14]  Lei Wang,et al.  Comparison of random forest, artificial neural networks and support vector machine for intelligent diagnosis of rotating machinery , 2018, Trans. Inst. Meas. Control.

[15]  I. Choi.  Comparison of the Disease Activity Score-28 Based on the Erythrocyte Sedimentation Rate and C-reactive Protein in Rheumatoid Arthritis , 2017 .

[16]  L. Bradbury,et al.  Transcriptome analysis of ankylosing spondylitis patients before and after TNF-α inhibitor therapy reveals the pathways affected , 2017, Genes and Immunity.

[17]  Joshua E. Lewis,et al.  Predicting clinical outcomes from large scale cancer genomic profiles with deep survival models , 2017, Scientific Reports.

[18]  Avanti Shrikumar,et al.  Learning Important Features Through Propagating Activation Differences , 2017, ICML.

[19]  D. M. van der Heijde,et al.  Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis , 2017, The New England journal of medicine.

[20]  Yuan Yu,et al.  TensorFlow: A system for large-scale machine learning , 2016, OSDI.

[21]  Tianqi Chen,et al.  XGBoost: A Scalable Tree Boosting System , 2016, KDD.

[22]  M. Dougados,et al.  Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. , 2015, The New England journal of medicine.

[23]  J. Curtis,et al.  A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol , 2015, Arthritis & rheumatology.

[24]  Ji-Eun Kim,et al.  Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis , 2015, PloS one.

[25]  L. Alfredsson,et al.  Familial risks and heritability of rheumatoid arthritis: role of rheumatoid factor/anti-citrullinated protein antibody status, number and type of affected relatives, sex, and age. , 2013, Arthritis and rheumatism.

[26]  I. de la Torre,et al.  Anti-TNF treatments in rheumatoid arthritis: economic impact of dosage modification , 2013, Expert review of pharmacoeconomics & outcomes research.

[27]  Q. Tong,et al.  TNF-α -857 and -1031 polymorphisms predict good therapeutic response to TNF-α blockers in Chinese Han patients with ankylosing spondylitis. , 2012, Pharmacogenomics.

[28]  A. Loft,et al.  Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry , 2012, Annals of the rheumatic diseases.

[29]  Piet Geusens,et al.  Predicting the outcome of ankylosing spondylitis therapy , 2011, Annals of the rheumatic diseases.

[30]  Gaël Varoquaux,et al.  Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..

[31]  C. Bombardier,et al.  Predictors for remission in rheumatoid arthritis patients: A systematic review , 2010, Arthritis care & research.

[32]  Jason Roy,et al.  Prediction Modeling Using EHR Data: Challenges, Strategies, and a Comparison of Machine Learning Approaches , 2010, Medical care.

[33]  Ji-Hyun Kim,et al.  Estimating classification error rate: Repeated cross-validation, repeated hold-out and bootstrap , 2009, Comput. Stat. Data Anal..

[34]  L. Coates,et al.  Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. , 2008, Rheumatology.

[35]  M. Brown,et al.  Breakthroughs in genetic studies of ankylosing spondylitis. , 2007, Rheumatology.

[36]  A. Silman,et al.  The British Society for Rheumatology Biologics Register. Ann Rheum Dis 2005;64 Suppl 4:iv42–3 , 2022 .

[37]  A. Silman,et al.  British Society for Rheumatology Biologics Register , 2003, Annals of the rheumatic diseases.

[38]  J. Smolen,et al.  Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[39]  J. Braun,et al.  Side effects of anti-TNF therapy: current knowledge. , 2002, Clinical and experimental rheumatology.

[40]  J J Anderson,et al.  Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. , 2001, Arthritis and rheumatism.

[41]  P Wordsworth,et al.  Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. , 1997, Arthritis and rheumatism.

[42]  Anil K. Jain,et al.  Artificial Neural Networks: A Tutorial , 1996, Computer.

[43]  J J Anderson,et al.  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[44]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[45]  I. Christensen,et al.  Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. , 2010, Arthritis and rheumatism.

[46]  P. Villiger,et al.  The −308 tumour necrosis factor-α gene polymorphism predicts therapeutic response to TNFα-blockers in rheumatoid arthritis and spondyloarthritis patients , 2007 .

[47]  P. Villiger,et al.  The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. , 2007, Rheumatology.

[48]  L. Breiman.  Random Forests , 2001, Machine Learning.

[49]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..